2-[[(2R)-2-amino-4-methylpentanoyl]amino]acetic acid | CAS:997-05-7

We serve 2-[[(2R)-2-amino-4-methylpentanoyl]amino]acetic acid CAS:997-05-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Chemical Name:  2-[[(2R)-2-amino-4-methylpentanoyl]amino]acetic acid
CAS.NO:997-05-7
Molecular Formula:C8H16N2O3
Molecular Weight:188.22400

Synonyms:
H-D-LEU-GLY-OH
N-D-leucyl-glycine
D-leucylglycine
DLEUCYL-GLYCINE extrapure
D-Leucyl=>ycin
N-D-Leucyl-glycin
D-LEU-GLY

Physical and Chemical Properties:
Density: 1.136g / cm3
Boiling point: 410.4ºC at 760mmHg
Flash point: 202ºC
Refractive index: 1.488

Specification:
Appearance: White powder solid
Purity:≥98%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at -20ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

Contact us for information like 2-[[(2R)-2-amino-4-methylpentanoyl]amino]acetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,D-LEU-GLY physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-[[(2R)-2-amino-4-methylpentanoyl]amino]acetic acid Use and application,N-D-leucyl-glycine technical grade,usp/ep/jp grade.


Related News: Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.N-Benzyl-N-methylethanolamine manufacturer These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. Beta Bionics is a Certified B Corporation? whose founders — in addition to Ed Damiano — include other parents of children with type 1 diabetes and people with type 1 diabetes. Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible.3,4-Dihydroxybenzaldehyde supplier It is foreseeable that in the future, the capacity and output of bulk APIs in China will decrease, the supply-demand relationship will be balanced, and prices and profits will gradually return to a more reasonable range. The era of low prices in the past will be gone forever. Individual APIs Varieties may even lose their price competitive advantage and move abroad.2-Naphthaleneboronic acid vendor There are also new directives that relate to US citizens.More serious cases could lead to potentially deadly conditions such as pneumonia and kidney failure, with the former having been reported among some patients in China.